vs
Side-by-side financial comparison of Gilead Sciences (GILD) and Cheniere Energy, Inc. (LNG). Click either name above to swap in a different company.
Gilead Sciences is the larger business by last-quarter revenue ($7.9B vs $5.4B, roughly 1.5× Cheniere Energy, Inc.). Cheniere Energy, Inc. runs the higher net margin — 42.8% vs 27.5%, a 15.3% gap on every dollar of revenue. On growth, Cheniere Energy, Inc. posted the faster year-over-year revenue change (20.3% vs 4.7%). Gilead Sciences produced more free cash flow last quarter ($3.1B vs $1.3B). Over the past eight quarters, Cheniere Energy, Inc.'s revenue compounded faster (14.3% CAGR vs 8.9%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Cheniere Energy, Inc. is an American liquefied natural gas (LNG) company headquartered in Houston, Texas.
GILD vs LNG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $5.4B |
| Net Profit | $2.2B | $2.3B |
| Gross Margin | 79.5% | — |
| Operating Margin | 25.0% | 70.8% |
| Net Margin | 27.5% | 42.8% |
| Revenue YoY | 4.7% | 20.3% |
| Net Profit YoY | 22.4% | 135.6% |
| EPS (diluted) | $1.75 | $10.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.9B | $5.4B | ||
| Q3 25 | $7.8B | $4.3B | ||
| Q2 25 | $7.1B | $4.5B | ||
| Q1 25 | $6.7B | $5.3B | ||
| Q4 24 | $7.6B | $4.5B | ||
| Q3 24 | $7.5B | $3.7B | ||
| Q2 24 | $7.0B | $3.1B | ||
| Q1 24 | $6.7B | $4.1B |
| Q4 25 | $2.2B | $2.3B | ||
| Q3 25 | $3.1B | $1.0B | ||
| Q2 25 | $2.0B | $1.6B | ||
| Q1 25 | $1.3B | $353.0M | ||
| Q4 24 | $1.8B | $977.0M | ||
| Q3 24 | $1.3B | $893.0M | ||
| Q2 24 | $1.6B | $880.0M | ||
| Q1 24 | $-4.2B | $502.0M |
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.8% | — |
| Q4 25 | 25.0% | 70.8% | ||
| Q3 25 | 42.8% | 42.3% | ||
| Q2 25 | 34.9% | 56.1% | ||
| Q1 25 | 33.6% | 18.2% | ||
| Q4 24 | 32.4% | 38.9% | ||
| Q3 24 | 11.8% | 44.7% | ||
| Q2 24 | 38.0% | 50.5% | ||
| Q1 24 | -64.6% | 28.0% |
| Q4 25 | 27.5% | 42.8% | ||
| Q3 25 | 39.3% | 24.4% | ||
| Q2 25 | 27.7% | 36.1% | ||
| Q1 25 | 19.7% | 6.7% | ||
| Q4 24 | 23.6% | 21.9% | ||
| Q3 24 | 16.6% | 24.2% | ||
| Q2 24 | 23.2% | 28.0% | ||
| Q1 24 | -62.4% | 12.2% |
| Q4 25 | $1.75 | $10.51 | ||
| Q3 25 | $2.43 | $4.75 | ||
| Q2 25 | $1.56 | $7.30 | ||
| Q1 25 | $1.04 | $1.57 | ||
| Q4 24 | $1.43 | $4.30 | ||
| Q3 24 | $1.00 | $3.93 | ||
| Q2 24 | $1.29 | $3.84 | ||
| Q1 24 | $-3.34 | $2.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | $1.1B |
| Total DebtLower is stronger | $24.9B | $22.5B |
| Stockholders' EquityBook value | $22.7B | $7.9B |
| Total Assets | $59.0B | $47.9B |
| Debt / EquityLower = less leverage | 1.10× | 2.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.0M | $1.1B | ||
| Q3 25 | $19.0M | $1.1B | ||
| Q2 25 | $69.0M | $1.6B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $4.4B |
| Q4 25 | $24.9B | $22.5B | ||
| Q3 25 | $24.9B | $22.0B | ||
| Q2 25 | $24.9B | $22.0B | ||
| Q1 25 | $25.0B | $22.5B | ||
| Q4 24 | $26.7B | $22.6B | ||
| Q3 24 | $23.2B | $22.5B | ||
| Q2 24 | $23.3B | $22.6B | ||
| Q1 24 | $25.2B | $21.4B |
| Q4 25 | $22.7B | $7.9B | ||
| Q3 25 | $21.5B | $6.7B | ||
| Q2 25 | $19.7B | $6.7B | ||
| Q1 25 | $19.2B | $5.6B | ||
| Q4 24 | $19.3B | $5.7B | ||
| Q3 24 | $18.5B | $5.1B | ||
| Q2 24 | $18.3B | $4.5B | ||
| Q1 24 | $17.5B | $4.3B |
| Q4 25 | $59.0B | $47.9B | ||
| Q3 25 | $58.5B | $45.1B | ||
| Q2 25 | $55.7B | $44.6B | ||
| Q1 25 | $56.4B | $43.5B | ||
| Q4 24 | $59.0B | $43.9B | ||
| Q3 24 | $54.5B | $43.1B | ||
| Q2 24 | $53.6B | $42.3B | ||
| Q1 24 | $56.3B | $42.9B |
| Q4 25 | 1.10× | 2.84× | ||
| Q3 25 | 1.16× | 3.25× | ||
| Q2 25 | 1.27× | 3.28× | ||
| Q1 25 | 1.30× | 4.03× | ||
| Q4 24 | 1.38× | 3.96× | ||
| Q3 24 | 1.26× | 4.42× | ||
| Q2 24 | 1.28× | 5.06× | ||
| Q1 24 | 1.44× | 5.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $2.1B |
| Free Cash FlowOCF − Capex | $3.1B | $1.3B |
| FCF MarginFCF / Revenue | 39.4% | 24.4% |
| Capex IntensityCapex / Revenue | 2.6% | 13.8% |
| Cash ConversionOCF / Net Profit | 1.52× | 0.89× |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | $2.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3B | $2.1B | ||
| Q3 25 | $4.1B | $1.4B | ||
| Q2 25 | $827.0M | $831.0M | ||
| Q1 25 | $1.8B | $1.2B | ||
| Q4 24 | $3.0B | $1.6B | ||
| Q3 24 | $4.3B | $1.4B | ||
| Q2 24 | $1.3B | $1.1B | ||
| Q1 24 | $2.2B | $1.2B |
| Q4 25 | $3.1B | $1.3B | ||
| Q3 25 | $4.0B | $738.0M | ||
| Q2 25 | $720.0M | $-193.0M | ||
| Q1 25 | $1.7B | $605.0M | ||
| Q4 24 | $2.8B | $1.1B | ||
| Q3 24 | $4.2B | $875.0M | ||
| Q2 24 | $1.2B | $613.0M | ||
| Q1 24 | $2.1B | $596.0M |
| Q4 25 | 39.4% | 24.4% | ||
| Q3 25 | 51.0% | 17.2% | ||
| Q2 25 | 10.2% | -4.3% | ||
| Q1 25 | 24.8% | 11.4% | ||
| Q4 24 | 37.4% | 24.0% | ||
| Q3 24 | 55.2% | 23.8% | ||
| Q2 24 | 17.2% | 19.5% | ||
| Q1 24 | 31.6% | 14.5% |
| Q4 25 | 2.6% | 13.8% | ||
| Q3 25 | 1.9% | 16.0% | ||
| Q2 25 | 1.5% | 22.7% | ||
| Q1 25 | 1.6% | 11.8% | ||
| Q4 24 | 1.9% | 12.7% | ||
| Q3 24 | 1.9% | 14.0% | ||
| Q2 24 | 1.9% | 16.0% | ||
| Q1 24 | 1.6% | 15.8% |
| Q4 25 | 1.52× | 0.89× | ||
| Q3 25 | 1.35× | 1.36× | ||
| Q2 25 | 0.42× | 0.51× | ||
| Q1 25 | 1.34× | 3.48× | ||
| Q4 24 | 1.67× | 1.68× | ||
| Q3 24 | 3.44× | 1.56× | ||
| Q2 24 | 0.82× | 1.27× | ||
| Q1 24 | — | 2.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
LNG
| Liquefied Natural Gas | $5.3B | 99% |
| Other | $103.0M | 2% |
| Regasification Service | $34.0M | 1% |
